Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events -Narrative (Details)

v2.4.0.8
Subsequent Events -Narrative (Details) (USD $)
 9 Months Ended 3 Months Ended 1 Months Ended
Sep. 30, 2014
Sep. 30, 2014
Lymphoseek
Oct. 31, 2014
Subsequent Event
Lymphoseek
Oct. 31, 2014
Subsequent Event
Chief Executive Officer
Oct. 31, 2014
Subsequent Event
Chief Executive Officer
Stock Option
Subsequent Event [Line Items]          
Employment agreement period       3 years  
Annual salary       $ 375,000  
Performance bonus (percent of base salary)       50.00%  
Options awarded (shares)         1,000,000
Exercise price of options (in dollars per share) $ 1.76     $ 1.26  
Stock based compensation, granted stock options' vesting period       3 years  
Exclusivity period   7 years      
Refund of FDA Registration fees     $ 1,100,000